The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Medtronic’s growth case has strengthened, but the dividend streak is not proof that earnings growth has caught up with sales. In FY26, revenue rose 5.8% organically while non-GAAP diluted earnings per share increased just 0.7% and non-GAAP operating margin fell 130 basis points. The first quarter of FY27 brought a sharp acceleration and higher guidance, but an extra fiscal week boosted that quarter’s growth. The new test is whether faster sales translate into sustained earnings and cash generation.
Can Medtronic keep raising its dividend?
Medtronic plc announced a quarterly dividend of $0.72 per ordinary share on June 3, 2026, equivalent to $2.88 annualized. The company described the increase as its 49th consecutive year of dividend increases. That is a record of past board decisions, not a promise about future ones. Medtronic’s FY26 results and dividend announcement
The operating figures provide context for the payout, but they do not establish its future. For FY26, Medtronic reported $5.4 billion in free cash flow, up 4.6%, and $7.3 billion in cash from operations. It returned $4.2 billion through dividends and net share repurchases combined; that total should not be read as dividends alone. Medtronic’s FY26 results and dividend announcement
Those numbers show that the business generated cash and returned capital in FY26. They do not, by themselves, establish a payout ratio, dividend safety, or whether the board will continue increasing the dividend. The available company results also do not answer whether Medtronic shares are attractively valued.
#1 Best Overall
Is growth finally the real story?
Growth was more visible in FY26, but the conversion from sales to earnings lagged. Medtronic reported $36.4 billion in revenue, up 8.4% as reported and 5.8% organically. Its non-GAAP diluted EPS was $5.53, a 0.7% increase. Non-GAAP operating profit rose 2.4%, while non-GAAP operating margin declined 130 basis points; GAAP operating margin was flat. Medtronic’s FY26 results Medtronic’s FY26 proxy statement
The contrast matters for an income investor. Sales growth can support future earnings and cash, but it does not ensure either will rise at the same pace. In FY26, free cash flow grew faster than non-GAAP EPS, while operating margin weakened on the company’s non-GAAP measure. The mix suggests progress in revenue and cash generation alongside a need for stronger margin and earnings conversion.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Growth was uneven across businesses
Medtronic described FY26 organic growth as high-single digits in Cardiovascular, low-single digits in Neuroscience and Medical Surgical, and high-single digits in Diabetes. These are company-reported descriptors, not identical growth rates across the portfolio. The company’s portfolio reporting changed for FY27, so segment comparisons across the periods require care. Diabetes figures may also be on a different basis around MiniMed’s March 2026 IPO; the FY27 outlook includes Diabetes revenue for the full fiscal year. Medtronic’s FY26 results Medtronic’s FY26 proxy statement
What changed in the first quarter of FY27?
Medtronic reported Q1 FY27 revenue of $9.8 billion, up 13.7% both as reported and organically. On September 1, 2026, it raised its FY27 guidance to organic revenue growth of 7.25%–7.75% and non-GAAP diluted EPS of $5.94–$6.00. Those are management’s expectations, not achieved results. CFO Thierry Piéton said, “The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance.” Medtronic’s September 1, 2026 Q1 FY27 release
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallAdjust for the 53-week fiscal year
FY27 is a 53-week fiscal year. Medtronic estimated that the extra week contributed approximately $570 million to Q1 organic revenue growth. That calendar effect makes the 13.7% figure a poor standalone basis for assuming the same pace will continue through the year. The raised full-year guidance is a more useful company outlook, though it too remains subject to execution and business conditions. Medtronic’s September 1, 2026 Q1 FY27 release
Keep the business scope in view
FY27 guidance includes Diabetes revenue for the full fiscal year. Medtronic’s FY26 disclosures describe the MiniMed IPO in March 2026 and a multi-step separation plan, making the business basis around the transition relevant when comparing periods. Organic-growth guidance and actual results should be interpreted with that scope in mind rather than treated as a perfectly like-for-like comparison. Medtronic’s September 1, 2026 Q1 FY27 release Medtronic’s FY26 proxy statement
Rank #4
What should dividend investors watch next?
The clearest question is whether sales growth increasingly shows up in earnings, margins, and cash. FY26 provides a mixed baseline: organic revenue grew 5.8%, non-GAAP EPS rose 0.7%, non-GAAP operating margin contracted, and free cash flow increased 4.6%. Q1 FY27 and the raised outlook improve the growth picture, but they do not yet demonstrate a full-year pattern.
- Earnings conversion: Compare subsequent non-GAAP EPS growth with organic revenue growth, keeping the measures labeled as company-defined non-GAAP and organic figures.
- Margin direction: Watch whether operating margin stabilizes or improves, distinguishing GAAP from non-GAAP reporting.
- Cash generation: Follow operating cash flow and free cash flow alongside dividend payments; shareholder-return totals that combine dividends and repurchases do not isolate the cost of the dividend.
- Comparable growth: Read FY27 results in light of the 53-week calendar and the full-year inclusion of Diabetes revenue.
- Guidance versus delivery: Treat the September 2026 ranges as management’s forecast until reported results confirm them.
Medtronic’s releases establish what management reported and expected as of September 1, 2026. They do not establish that FY27 guidance will be met or that the dividend streak will continue. The growth story is stronger than at FY26 year-end; proving that growth can consistently convert into earnings and cash is the challenge now.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
